樂鑫科技(688018.SH):樂鑫香港擬減持不超40萬股
格隆匯8月8日丨樂鑫科技(688018.SH)公佈,樂鑫香港擬通過集中競價方式減持所持有的公司股份不超40萬股,不超過公司目前總股本的0.50%,將於公吿日起十五個交易日後進行,期間為2022年8月30日至2023年2月28日。
減持價格不低於120元/股,具體將根據減持時的市場價格確定;若在減持計劃實施期間公司發生送股、資本公積轉增股本、配股等股份變更事項的,將根據相關規定對擬減持數量進行相應調整。
在股份減持期間內,樂鑫香港將遵守在任意連續90日內通過集中競價交易方式減持股份的總數不超過公司股份總數的1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.